A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer
Repeated, prostate-specific antigen–based screening with a 4-yr interval in men aged 55–69 yr reduces prostate cancer–specific mortality and metastatic prostate cancer after a median follow-up of 21 yr. Additionally, coinciding overdiagnosis is lower than previously suggested.
